Novo Nordisk to expand R&D center in China

Tuesday, September 25, 2012 09:58 AM

Novo Nordisk, a Denmark-based biopharmaceutical company and the first multinational company to open a research center in China in 1997, is reaffirming its long-term commitment to the country by investing an additional $100 million to expand its state-of-the-art science facilities in Beijing.

The new 12,000 square meter center will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth. With this expansion, Novo Nordisk also fulfills its key strategic objective to ensure the full range of protein research capabilities in China.

"We see the investment in this new R&D facility as a win-win opportunity for both Novo Nordisk and China,” said Mads Krogsgaard Thomsen, chief science officer and executive vice president, Novo Nordisk. “Novo Nordisk recognizes the strong science being performed in China and we want to bring innovation from Chinese scientists into our company to help tackle the growing burden of diabetes and other chronic diseases throughout the world.”

The site in Beijing has already contributed significantly to the R&D portfolio in both diabetes and biopharmaceutical target disease areas. The new, expanded facility will enable even stronger contributions from the science team in China across the range of Novo Nordisk's protein technology, biology and pharmacology research activities.

Novo Nordisk's global research organization, including its other sites in Denmark and the U.S., is set up to facilitate best practice-sharing and scientific sparring between employees at the different locations to ensure the most efficient and successful pipeline innovation and development.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 22

DaVita combines its two research CRO units to create an end-to-end CRO focused on kidney, end-stage renal disease

New crop of clinical trial matching services use patient’s molecular, genomic data for better fit

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs